ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 456

Time from First Symptom Onset to First Advanced Therapy Amongst RA Patients in Latin America

Ivanio Pereira1, Valderilio F Azevedo2, Wilson Bautista-Molano3, Julio Casasola4, Generoso Guerra5, David Vega-Morales6, Enrique R Soriano7, Diana Rocio Gil8, José Antonio Maldonado-Cocco9, Leandro Aldunate10 and Steve Lobosco11, 1Rheumatology, Universidade Federal de Santa Catarina, Hospital Universitário, Divisão de Reumatologia.Brazil, Florianopolis, Brazil, 2Adjunct Professor of Rheumatology, Federal University of Paraná; Brazil, Curitiba, Brazil, 3School of Medicine, Universidad Militar Nueva Granada and Rheumatology Department Hospital Militar. Colombia, Bogotá, Colombia, 4Rheumatology, Hospital General de Mexico, Mexico, Mexico, 5Centro Médico Paitilla Internal Medicine and Rheumatology Department. Panama, Panama City, Panama, 6Universidad Autónoma de Nuevo León. Rheumatology Service, Internal Medicine Department, Hospital Universitario "Dr. José Eleuterio González". Mexico, Monterrey, Mexico, 7Argentina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 8ART Medica - Hospital Universitario Mayor MEDERI Internal Medicine and Rheumatology. Colombia., Bogota, Colombia, 9Buenos Aires University, Consulting Professor of Rheumatology, Buenos Aires University. Argentina, Buenos Aires, Argentina, 10Immunology, Janssen Latin America, Buenos Aires, Argentina, 11Adelphi, Immunology Director- Adelphi Group, Manchester, United Kingdom

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords:

Session Information

Date: Sunday, November 5, 2017

Title: Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: To understand the RA patient pathway in Latin America from first symptom onset; including time to diagnosis and to first advanced treatment.

Methods: Data from the 2015 RA Disease Specific Programme (DSP), a cross-sectional, multi-national survey of patients and rheumatologists conducted in Brazil, Argentina, Mexico, Colombia, Venezuela were analyzed against 2014 DSP data from the US and 5EU. Rheumatologists (n=188 Latin America, n=113 US, n=340 EU) completed forms containing patient demographics, age at first RA symptoms, age at RA diagnosis, age at csDMARD initiation and age at bDMARD initiation. Continuous data were tested using t tests.

Results: A total of 801 Latin America, 843 US and 2536 EU RA patients were included in this analysis. Current mean age across Latin America was 51.9 years and 82.8% female. Mean age of patients at RA symptom onset was 40.6 years, with age at diagnosis 42.6 years; resulting in a 2.2 year (3.9 SD) wait from first experiencing symptoms to receiving a confirmed diagnosis. Patients in Latin America waited 2.6 years (5.7 SD) from the point of RA diagnosis to initiation of first csDMARD vs. 1.0 years US (3.2 SD) and 1.1 years EU (3.0 SD) (both p<0.001), and 6.4 years (7.4 SD) from RA diagnosis to initiation of first bDMARD therapy vs. 3.9 years US (5.6 SD) and 5.2 years EU (5.7 SD) (both p<0.001).

Conclusion: RA patients in Latin America wait over 2 years from symptom onset to diagnosis and significantly longer than their US and EU counterparts to receive csDMARD and Biologic therapy. This highlights a clear need to shorten RA diagnosis times and time to treatment initiation.

Disclosure: I. Pereira, None; V. F. Azevedo, AbbVie, Eli Lilly, Genentech, GSK, Pfizer Inc, UCB, 2,AbbVie, Merck-Serono, Novartis, Pfizer Inc, 5,AbbVie, Janssen, Merck-Serono, Novartis, Pfizer Inc, Sanofi, 8; W. Bautista-Molano, None; J. Casasola, None; G. Guerra, None; D. Vega-Morales, None; E. R. Soriano, AbbVie, Janssen, Novartis, Pfizer Inc, UCB, 2,AbbVie, Janssen, Novartis, Pfizer Inc, UCB, 5,AbbVie, Bristol-Myers Squibb, Janssen, Novartis, Pfizer Inc, Roche, UCB, 8; D. Rocio Gil, None; J. A. Maldonado-Cocco, None; L. Aldunate, Janssen Pharmaceutica Product, L.P., 3; S. Lobosco, Adelphi, 3.

To cite this abstract in AMA style:

Pereira I, Azevedo VF, Bautista-Molano W, Casasola J, Guerra G, Vega-Morales D, Soriano ER, Rocio Gil D, Maldonado-Cocco JA, Aldunate L, Lobosco S. Time from First Symptom Onset to First Advanced Therapy Amongst RA Patients in Latin America [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/time-from-first-symptom-onset-to-first-advanced-therapy-amongst-ra-patients-in-latin-america/. Accessed .

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/time-from-first-symptom-onset-to-first-advanced-therapy-amongst-ra-patients-in-latin-america/